Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

reatment due to viral breakthrough. RVR is defined as undetectable virus (HCV-RNA) in plasma on or before week 4 of boceprevir treatment.

"The high response rates seen with boceprevir in this study are very exciting, especially given that genotype 1 is the most common and hardest to treat form of hepatitis C," said Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and lead investigator of the study. "Boceprevir was well tolerated by patients in this study, and the use of the 4-week lead-in prior to the addition of boceprevir appears to reduce the incidence of viral breakthrough regardless of treatment duration and may improve SVR over a 48-week treatment period."

The rationale for this novel lead-in treatment regimen is based on the fact that both PEGINTRON and REBETOL reach steady-state concentrations by week 4, so patients have the protease inhibitor added at a time when the backbone drug levels have been optimized. In addition, the patient's immune system will have been activated and primed by PEGINTRON at the time that boceprevir is added to the regimen. This approach may minimize the period of time when there is a "functional monotherapy" with a direct antiviral, potentially reducing the likelihood for the development of resistance.

Safety data from the study showed that the most common adverse events reported in the boceprevir arms were fatigue, anemia, nausea and headache. No increase in skin adverse events (rash or pruritus) was observed in the boceprevir arms beyond what was seen in the PEGINTRON and REBETOL control arm.

Treatment discontinuations due to adverse events were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm. Treatment discontinuations for boceprevir patients due to viral breakthrough were fewer in the 2
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... SAN DIEGO, Feb. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... patient enrollment in its bioequivalence study of ANX-514 (docetaxel ... announce results from this study in the second quarter ... chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved ...
... to monitor health outcomes in Fresno, California LOS ALTOS, ... Foundation (GHRF) today announced that it has received a ... treatment in California,s Central Valley, a region with the ... grant will help fund data collection and analysis at ...
Cached Medicine Technology:ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 2ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 3Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley 2
(Date:7/13/2014)... in The Lancet Neurology calls for ... term neurological problems that repeated concussions can cause. ... of sports-related traumatic brain injury (TBI), and the ... amyotrophic lateral sclerosis, and other neurological disorders, say ... concerning, is that even when the symptoms of ...
(Date:7/13/2014)... 13, 2014 Carolinas Healthcare System celebrated ... the Carolinas HealthCare System - Anson located in Anson ... Anson Community Hospital in Wadesboro. , Located on U.S. ... from the previous facility. Situated on a 10-acre site, ... an emergency room drop-off, helipad, healing garden, and 15 ...
(Date:7/13/2014)... portable, microchip-based test for diagnosing type-1 diabetes could ... understand the disease, according to the device,s inventors ... Described in a paper to be published online ... test employs nanotechnology to detect type-1 diabetes outside ... two main forms of diabetes mellitus, which are ...
(Date:7/13/2014)... Victorian Hotel has recently announced that it ... bikes for its "Cycle the City" program, which encourages ... the area using a rental bicycle, available for just ... call Vancouver home, as it is a city with ... journeys through the countryside. Vancouver hotel rooms often play ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... high health-care costs it has become a burden both on ... as a respite comes a new cardio drug that negates ... ,The drug is in the African-American heart failure patients where ... Angus, M.D., M.P.H., professor of critical care medicine at the ...
... A liver transplant operation has been conducted on a six-year-old ... underwent the surgery celebrates his birthday on 19 December 2005. ... 'The kid is still in ICU but is responding well ... hope his condition will be normal soon.' , ,He ...
... Clinic say that the flagship breast cancer drug, tamoxifen might ... genetic variation. // ,This particular variant gene has the ... is vital to activate tamoxifen against breast cancer. The study ... of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an ...
... is responsible for the death of Rene Anderson, a diabetic ... was prescribed to Mrs. Anderson to ease the numbness and ... // ,The medicine is reported to have resulted disturbed ... an intoxicated and confused state. Here her condition continued to ...
... formed a new cabinet committee to plan strategies to fight ... said that though the United Kingdom //Government has taken various ... spread but the committee feels still a lot has to ... committee feels that the Government should organize the food sector ...
... easily subsided by administering sweet to children now has a ... ,They have reported that the analgesic efficacy of sweet ... sweet taste and by the child's weight status. This appears ... just because they taste good, but also because sweets make ...
Cached Medicine News:Health News:A cost effective heart failure drug hits the market! 2Health News:Sweet pain releiver! 2
... Workstations provide comprehensive neurological monitoring in ... unit to accurately access your patients ... 15 years experience, and a long ... neurological monitoring systems have a proven ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... system especially designed for surgical monitoring and ... channels and is equipped with two headboxes ... can be independently configured as either a ... Endeavor amplifiers are based on the Firewire ...
Medicine Products: